Analyst
William Blair
Equibles does not estimate personal net worth.
Myles Minter is recorded as Analyst at William Blair. Myles Minter has spoken on 12 earnings calls and 4 other investor events across 10 companies, most recently for Moderna, Inc. on November 6, 2026. Those appearances were for Neurocrine Biosciences Inc (NBIX), Axsome Therapeutics, Inc. (AXSM), Argenx SE (ARGX), Arcturus Therapeutics Holdings Inc. (ARCT), Moderna, Inc. (MRNA) and 5 other companies. The companies whose calls Myles Minter spoke on are classified in the Healthcare sector.
“I actually had just a question on neurovirus. I think at your last quarterly update, you indicated you were going to enroll another cohort. Now you're not, and you're going to the regulators just wondering, you know, what changed there and what you're hoping to get out of those regulatory discussions.”
“Just curious about the terminology about a collaboration with the FDA when you're talking about BICAT-XR.”
“So just on FB102 and the Phase 3 celiac trial design, can you comment a little bit more there? I mean, obviously the length and particularly the type of gluten challenge appears to be a variable across trials here.”
“I know you've been talking with regulators, and it seems like you've got alignment here with amending this phase two to include 2601, pending the actual GLP studies look clean.”
“I know you've been talking with regulators, and it seems like you've got alignment here with amending this phase I'm wondering whether you talked about endpoints, particularly as it relates to, you know, maybe a potential accelerated approval for the program.”
William Blair
Analyst
Source not stated
Drug Manufacturers - Specialty & Generic · Healthcare
ARGX
Biotechnology · Healthcare
MRNA
Biotechnology · Healthcare
BIIB
Drug Manufacturers - General · Healthcare
ALEC
Biotechnology · Healthcare
